LENSAR Reports Third Quarter 2023 Results and Provides Business Update
Increased ALLY® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation...
News
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected...
Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2023) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX" or the "Company"),...
Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
SAN FRANCISCO, CA / ACCESSWIRE / November 9, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company,...
Nasdaq-Listed AGAPE Forges Ahead with Sustainable Energy Business
KUALA LUMPUR, MALAYSIA / ACCESSWIRE / November 9, 2023 / Homegrown Nasdaq listed AGAPE ATP Corporation ("ATPC" or the "Company")(NASDAQ:ATPC)...
Radical Imaging Announces Integration of FlexView Inside Agora Care
Integration will enable Agora Care to focus on its strengths in solving today's challenges in long-term storage and access to...
Blue Cross and Blue Shield of Minnesota Foundation Awards $1.5M in Grants; Welcomes Kristine Rhodes to Board of Directors
EAGAN, MN / ACCESSWIRE / November 9, 2023 / The Blue Cross and Blue Shield of Minnesota Foundation has awarded...
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF),...
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
PharmAla, University of Calgary, and Heroic Hearts Canada to partner on a groundbreaking observational trialVANCOUVER, British Columbia, Nov. 09, 2023...
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered LivesMALVERN, Pa., Nov. 09, 2023 (GLOBE...
Evoke Pharma Reports Third Quarter 2023 Financial Results
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial...
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline...
Inozyme Pharma to Participate in Upcoming Investor Conferences
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease...
SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent
SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75$4.5 Million Bridge Financing led by North South VenturesComposition...
Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York
Represents first sales by the Company into an ambulatory surgery center Follows successful evaluation by Island Ambulatory Surgery Center’s founder...
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million
- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia...
New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men
One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across SexesSANTA CLARA, Calif., Nov. 09, 2023 (GLOBE...
Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and...
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of...